AG˹ٷ

STOCK TITAN

[Form 4] Freedom Holding Corp. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Ionis Pharmaceuticals (IONS) � CEO Form 4 insider transaction dated 07/30/25

Chief Executive Officer Brett P. Monia exercised 2,432 non-qualified stock options at an exercise price of $32.60 (transaction code M) and immediately sold the same 2,432 shares of common stock at $45.00 (transaction code S) pursuant to a Rule 10b5-1 plan adopted 08/13/24. Following the sale, Monia’s direct holdings stand at 179,820 common shares, while he retains 99,057 options outstanding. The options exercised were granted 01/03/23 and expire 01/02/32.

The sale represents roughly 1.4 % of his direct equity stake and appears routine given the pre-arranged trading plan. There is no indication of additional material events or changes to company fundamentals within the filing.

Ionis Pharmaceuticals (IONS) � Transazione interna del CEO Form 4 datata 30/07/25

Il Chief Executive Officer Brett P. Monia ha esercitato 2.432 opzioni azionarie non qualificate al prezzo di esercizio di 32,60 $ (codice transazione M) e ha immediatamente venduto le stesse 2.432 azioni ordinarie a 45,00 $ (codice transazione S) secondo un piano Rule 10b5-1 adottato il 13/08/24. Dopo la vendita, le partecipazioni dirette di Monia ammontano a 179.820 azioni ordinarie, mentre mantiene 99.057 opzioni ancora in essere. Le opzioni esercitate erano state concesse il 03/01/23 e scadranno il 02/01/32.

La vendita rappresenta circa l'1,4% della sua partecipazione azionaria diretta e appare di routine, dato il piano di trading predefinito. Non vi sono indicazioni di eventi materiali aggiuntivi o cambiamenti nei fondamentali dell'azienda all'interno del documento.

Ionis Pharmaceuticals (IONS) � Transacción interna del CEO Formulario 4 fechada 30/07/25

El Director Ejecutivo Brett P. Monia ejerció 2.432 opciones sobre acciones no calificadas a un precio de ejercicio de 32,60 $ (código de transacción M) y vendió inmediatamente las mismas 2.432 acciones ordinarias a 45,00 $ (código de transacción S) conforme a un plan Rule 10b5-1 adoptado el 13/08/24. Tras la venta, las participaciones directas de Monia ascienden a 179.820 acciones ordinarias, mientras que conserva 99.057 opciones pendientes. Las opciones ejercidas fueron concedidas el 03/01/23 y expiran el 02/01/32.

La venta representa aproximadamente el 1,4 % de su participación directa en acciones y parece rutinaria dado el plan de trading preestablecido. No hay indicios de eventos materiales adicionales o cambios en los fundamentos de la empresa en el documento.

Ionis Pharmaceuticals (IONS) � CEO 내부� 거래 Form 4, 2025� 7� 30일자

최고경영� Brett P. Monia� 행사 가� $32.60� 2,432개의 비자� 스톡옵션� 행사(거래 코드 M)하고, 2024� 8� 13� 채택� Rule 10b5-1 계획� 따라 동일� 2,432� 보통주를 즉시 $45.00(거래 코드 S)� 매도했습니다. 매도 � Monia� 직접 보유 주식은 179,820주이�, 미행� 옵션은 99,057주입니다. 행사� 옵션은 2023� 1� 3� 부여되었으� 2032� 1� 2� 만료됩니�.

이번 매도� 그의 직접 지분의 � 1.4%� 해당하며, 사전� 계획� 거래 계획� 따라 일상적인 것으� 보입니다. 제출� 문서 내에 추가적인 중대� 사건이나 회사 기본 사항� 변화는 나타나지 않습니다.

Ionis Pharmaceuticals (IONS) � Transaction initiée par le CEO selon le Formulaire 4 daté du 30/07/25

Le Directeur Général Brett P. Monia a exercé 2 432 options d'achat d'actions non qualifiées à un prix d'exercice de 32,60 $ (code transaction M) et a immédiatement vendu les mêmes 2 432 actions ordinaires à 45,00 $ (code transaction S) conformément à un plan Rule 10b5-1 adopté le 13/08/24. Après la vente, la détention directe de Monia s'élève à 179 820 actions ordinaires, tandis qu'il conserve 99 057 options en circulation. Les options exercées ont été attribuées le 03/01/23 et expirent le 02/01/32.

Cette vente représente environ 1,4 % de sa participation directe en actions et semble être une opération de routine, compte tenu du plan de trading préétabli. Aucun événement matériel supplémentaire ni changement fondamental de l'entreprise n'est indiqué dans le dépôt.

Ionis Pharmaceuticals (IONS) � CEO Insider-Transaktion Form 4 vom 30.07.25

Chief Executive Officer Brett P. Monia hat 2.432 nicht qualifizierte Aktienoptionen zum Ausübungspreis von 32,60 $ (Transaktionscode M) ausgeübt und unmittelbar danach dieselben 2.432 Stammaktien zu 45,00 $ (Transaktionscode S) gemäß einem am 13.08.24 angenommenen Rule 10b5-1 Plan verkauft. Nach dem Verkauf hält Monia direkt 179.820 Stammaktien, während er noch 99.057 ausstehende Optionen besitzt. Die ausgeübten Optionen wurden am 03.01.23 gewährt und laufen am 02.01.32 ab.

Der Verkauf entspricht etwa 1,4 % seines direkten Aktienanteils und erscheint routinemäßig angesichts des vorab vereinbarten Handelsplans. Im Formular gibt es keine Hinweise auf weitere wesentliche Ereignisse oder Änderungen der Unternehmensgrundlagen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small, pre-planned CEO share sale—neutral signal for investors.

Monia converted 2,432 options into stock at $32.60 and sold them at $45, realising a ~$30k gross gain. Because the sale was executed under an established Rule 10b5-1 plan and equals only ~1.4 % of his 180k-share position, it does not materially alter insider ownership or suggest a directional view on Ionis fundamentals. No other derivatives were affected; 99,057 options remain. Overall, the filing is routine and should have minimal market impact.

Ionis Pharmaceuticals (IONS) � Transazione interna del CEO Form 4 datata 30/07/25

Il Chief Executive Officer Brett P. Monia ha esercitato 2.432 opzioni azionarie non qualificate al prezzo di esercizio di 32,60 $ (codice transazione M) e ha immediatamente venduto le stesse 2.432 azioni ordinarie a 45,00 $ (codice transazione S) secondo un piano Rule 10b5-1 adottato il 13/08/24. Dopo la vendita, le partecipazioni dirette di Monia ammontano a 179.820 azioni ordinarie, mentre mantiene 99.057 opzioni ancora in essere. Le opzioni esercitate erano state concesse il 03/01/23 e scadranno il 02/01/32.

La vendita rappresenta circa l'1,4% della sua partecipazione azionaria diretta e appare di routine, dato il piano di trading predefinito. Non vi sono indicazioni di eventi materiali aggiuntivi o cambiamenti nei fondamentali dell'azienda all'interno del documento.

Ionis Pharmaceuticals (IONS) � Transacción interna del CEO Formulario 4 fechada 30/07/25

El Director Ejecutivo Brett P. Monia ejerció 2.432 opciones sobre acciones no calificadas a un precio de ejercicio de 32,60 $ (código de transacción M) y vendió inmediatamente las mismas 2.432 acciones ordinarias a 45,00 $ (código de transacción S) conforme a un plan Rule 10b5-1 adoptado el 13/08/24. Tras la venta, las participaciones directas de Monia ascienden a 179.820 acciones ordinarias, mientras que conserva 99.057 opciones pendientes. Las opciones ejercidas fueron concedidas el 03/01/23 y expiran el 02/01/32.

La venta representa aproximadamente el 1,4 % de su participación directa en acciones y parece rutinaria dado el plan de trading preestablecido. No hay indicios de eventos materiales adicionales o cambios en los fundamentos de la empresa en el documento.

Ionis Pharmaceuticals (IONS) � CEO 내부� 거래 Form 4, 2025� 7� 30일자

최고경영� Brett P. Monia� 행사 가� $32.60� 2,432개의 비자� 스톡옵션� 행사(거래 코드 M)하고, 2024� 8� 13� 채택� Rule 10b5-1 계획� 따라 동일� 2,432� 보통주를 즉시 $45.00(거래 코드 S)� 매도했습니다. 매도 � Monia� 직접 보유 주식은 179,820주이�, 미행� 옵션은 99,057주입니다. 행사� 옵션은 2023� 1� 3� 부여되었으� 2032� 1� 2� 만료됩니�.

이번 매도� 그의 직접 지분의 � 1.4%� 해당하며, 사전� 계획� 거래 계획� 따라 일상적인 것으� 보입니다. 제출� 문서 내에 추가적인 중대� 사건이나 회사 기본 사항� 변화는 나타나지 않습니다.

Ionis Pharmaceuticals (IONS) � Transaction initiée par le CEO selon le Formulaire 4 daté du 30/07/25

Le Directeur Général Brett P. Monia a exercé 2 432 options d'achat d'actions non qualifiées à un prix d'exercice de 32,60 $ (code transaction M) et a immédiatement vendu les mêmes 2 432 actions ordinaires à 45,00 $ (code transaction S) conformément à un plan Rule 10b5-1 adopté le 13/08/24. Après la vente, la détention directe de Monia s'élève à 179 820 actions ordinaires, tandis qu'il conserve 99 057 options en circulation. Les options exercées ont été attribuées le 03/01/23 et expirent le 02/01/32.

Cette vente représente environ 1,4 % de sa participation directe en actions et semble être une opération de routine, compte tenu du plan de trading préétabli. Aucun événement matériel supplémentaire ni changement fondamental de l'entreprise n'est indiqué dans le dépôt.

Ionis Pharmaceuticals (IONS) � CEO Insider-Transaktion Form 4 vom 30.07.25

Chief Executive Officer Brett P. Monia hat 2.432 nicht qualifizierte Aktienoptionen zum Ausübungspreis von 32,60 $ (Transaktionscode M) ausgeübt und unmittelbar danach dieselben 2.432 Stammaktien zu 45,00 $ (Transaktionscode S) gemäß einem am 13.08.24 angenommenen Rule 10b5-1 Plan verkauft. Nach dem Verkauf hält Monia direkt 179.820 Stammaktien, während er noch 99.057 ausstehende Optionen besitzt. Die ausgeübten Optionen wurden am 03.01.23 gewährt und laufen am 02.01.32 ab.

Der Verkauf entspricht etwa 1,4 % seines direkten Aktienanteils und erscheint routinemäßig angesichts des vorab vereinbarten Handelsplans. Im Formular gibt es keine Hinweise auf weitere wesentliche Ereignisse oder Änderungen der Unternehmensgrundlagen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kerr Jason M

(Last) (First) (Middle)
40 WALL STREET, 58TH FLOOR

(Street)
NEW YORK NY 10005

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Freedom Holding Corp. [ FRHC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 07/24/2025 A 3,309(1) A $0 3,309 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Mr. Kerr was awarded 3,309 restricted shares of common stock of Freedom Holding Corp. (the "Company") on July 24, 2025, under the Company 2019 Equity Incentive Plan. Assuming satisfaction of applicable vesting conditions, which include continuous service with the Company and market price conditions tied to the performance of the Company's common shares, vesting of the shares occurred on July 24, 2025.
/s/ Jason M. Kerr 08/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Freedom Hldg Corp Nev

NASDAQ:FRHC

FRHC Rankings

FRHC Latest News

FRHC Latest SEC Filings

FRHC Stock Data

11.55B
18.06M
70.51%
2.08%
1.12%
Financial Conglomerates
Security Brokers, Dealers & Flotation Companies
United States
NEW YORK, NY